Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arteris, Inc. (Nasdaq: AIP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Arteris describes itself as a global leader in system IP used in semiconductors, and its filings offer formal detail on the financial and operational aspects behind that business.
Among the key documents are current reports on Form 8-K, which Arteris uses to furnish press releases announcing quarterly financial results and other material events. For example, the company has filed 8-Ks referencing press releases on results for quarters ended June 30 and September 30, including metrics such as revenue, licensing and royalty performance, operating loss, and Remaining Performance Obligations. These filings give investors structured insight into how Arteris’ licensing, support and maintenance, and variable royalty revenue streams are evolving.
Users can also review other periodic reports, such as Forms 10-Q and 10-K when available, to understand topics like segment performance, risk factors, and detailed financial statements that complement the high-level figures cited in press releases. For those interested in governance and ownership, SEC filings are the place where proxy statements and beneficial ownership reports would appear.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy filings. Instead of reading every line of a multi-page 10-K or 10-Q, users can rely on AI explanations to quickly identify revenue trends, key risks, and notable changes. The platform also surfaces insider transaction reports on Form 4 when filed, helping investors monitor trading activity by Arteris officers and directors.
By using this page, investors and researchers can efficiently navigate Arteris’ official SEC disclosures, from earnings-related 8-Ks to comprehensive annual and quarterly reports, supported by AI tools that make complex documents easier to interpret.
Viana Family Trust U/A DTD 07/12/2007 filed a Rule 144 notice reporting 20,000 shares of Common Stock to be sold on or about 04/24/2026 on NASDAQ. The filing notes prior 10b5-1 sales of 20,000 shares on 04/17/2026 for $442,168.
Insider sale filed on Form 144: reported disposition of 5,000 shares. The filing shows 5,000 restricted stock units granted 03/15/2022 and a 10b5-1 sale of 5,000 common shares on 04/14/2026 reporting proceeds of $100,254.00. The filing lists the broker as Morgan Stanley Smith Barney LLC.
Arteris, Inc. director Saiyed Atiq Raza, through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, reported open‑market sales of a total of 90,000 shares of Arteris common stock at weighted average prices around $22 per share under a pre‑arranged Rule 10b5‑1 trading plan. After these transactions, the trust holds 300,000 shares indirectly, and Raza also holds 20,839 shares directly.
Arteris, Inc. director Antonio J. Viana reported an open‑market sale of common stock through the Viana Family Trust. On April 17, 2026, the trust sold 20,000 shares at a weighted average price of $22.1084 per share under a pre‑arranged Rule 10b5-1 trading plan adopted on June 10, 2025. After this sale, the trust held 144,620 shares of Arteris common stock, while Viana also directly held 20,840 shares, indicating he retains a substantial equity position.
Arteris, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 2, 2026 to elect three Class II directors and ratify Deloitte & Touche LLP as independent auditor for 2026.
The company highlights continued growth since its 2021 IPO, reaching $70 in revenue in 2025 with customers shipping over 4 billion SoCs containing Arteris system IP, and expanding its SoC integration automation products. In January 2026 Arteris acquired Cycuity, Inc., adding semiconductor cybersecurity verification technology.
The record date is April 9, 2026, when 46,092,618 shares of common stock were outstanding. The board has seven members, a classified structure, and a lead independent director, and reports continued use of performance-based bonuses, equity awards and a formal clawback and insider trading policy. Arteris remains an “emerging growth company” with scaled executive compensation disclosure.
AIP filing a Form 144 notice reporting proposed sales of 90,000 shares of Common stock and a series of recent 10b5-1 dispositions. The excerpt lists multiple sale dates and amounts, including 106,031 and 73,610 shares on March and February 2026.
Arteris, Inc. Chief Operating Officer Laurent R. Moll executed an open-market sale of common stock. On April 14, 2026, he sold 13,448 shares at a weighted average price of $20.0313 per share in multiple transactions.
After this sale, he directly holds 265,530 shares of Arteris common stock. The transaction was carried out under a Rule 10b5-1 trading plan that he adopted on March 12, 2026, indicating the sales were pre-scheduled rather than opportunistic. Individual trade prices ranged from $19.90 to $20.22 per share.
Arteris, Inc. director Raman Chitkara sold shares in an open-market transaction. On this date, he sold 5,000 shares of common stock at a weighted average price of $20.0508 per share, with individual sale prices ranging from $20.00 to $20.13. After the sale, he directly holds 152,867 shares, indicating the transaction represents a small portion of his overall position.